ARISE: A multi-centre prospective non-interventional study investigating the clinical effectiveness of RyzodegÂ®(Insulin Degludec/Insulin Aspart) in patients with type 2 diabetes mellitus in a real-world setting - ARISE

ovo Nordisk India Private Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Informed consent obtained before any study-related activities. Study-related activities are any procedures related to recording of data according to the protocol.
•2.The decision to initiate or switch into treatment with commercially available RyzodegÂ® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before, and independently from, the decision to include the patient in this study.
•3.Male or female, age above or equal to 18 years at the time of signing informed consent.
•4.Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than RyzodegÂ® for at least 26 weeks prior to signing informed consent.
•5.Available and documented Glycosylated haemoglobin (HbA1c) value less than or equal to 12 weeks prior to signing informed consent.

•1.Hypersensitivity to the active substance or to any of the excipients as specified in the RyzodegÂ® local label.
•2.Previous participation in this study. Participation is defined as signed informed consent.
•3.Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
•4.Previous treatment with RyzodegÂ®.

发起方

ovo Nordisk India Private Ltd